Hi Sergei,
Starting materials for API often times are produced non-GMP. I think it is entirely possible to use material from R&D lab as starting material for GMP API manufacturing.
I assume here that your API will be used in human. Is your API going to be used in early stage development (i.e. Phase 1) vs later stage? Other than your company's quality philosophy/conservativeness, the phase of development greatly affects how stringent your documentation and analytical testing will be. As a start, FDA's Guidance for Industry: cGMP for Phase 1 Investigational Drugs provides some information on the view of the agency (well at least the FDA) for Phase 1 drug.
If this is for Phase 1, I would expect good description of the procedure, raw materials, reagents, and solvents used. Collecting all the CoAs is a good practice but one should, at least, record all the suppliers and lot numbers. The key is to have some traceability of materials. Analytical methods for starting materials are likely not the most sophisicated especially at early stage, but they should give you confidence on the identity and purity of the starting material going into the GMP API manufacturing (hard to pin point the analytical techniques to use because that depends on your material).
Hope it helps. Happy to discuss more.
-------------------------------------------
Priscilla White RAC
Associate Director, Pharmaceutical Development
Infinity Pharmaceuticals, Inc.
Cambridge MA
United States
-------------------------------------------
Original Message:
Sent: 12-10-2014 16:46
From: Sergei Poletaev
Subject: Use of non-GMP starting material for API manufacture
Hi all,
Is there any way to use materials produced in an R&D lab (non-GMP) as starting materials for API manufacturing. And if so, what sort of tests would be required to quality such materials for said purpose? Any help with clarifying would be appreciated.
Thanks.
Regards,
Sergei Poletaev